### Results

**Objective**

The objective of this analysis was to assess tralokinumab in patients with moderate-to-severe AD receiving tralokinumab combined with TCS in the ECZTRA 3 trial.

**Patients**

Patients were aged ≥12 years with a diagnosis of AD of at least 6 months’ duration and with at least one active lesion. The primary endpoint was assessed at week 16 for the initial 16-week treatment period.

**Study design**

Patients were randomized to receive either tralokinumab q2w or q4w plus placebo or TCS for an initial 16-week treatment period. Patients who achieved EASI-75 and IGA-0/1 at week 16 continued to week 32 without rescue medication.

**Concomitant TCS use during ECZTRA 3**

TCS (strengths ≤1%, ≤0.1%, ≤0.05%) were used in 44.0%, 46.3%, and 44.5% of patients in the tralokinumab q2w, q4w, and placebo groups, respectively.

**TCS use during the initial treatment period**

Cumulative TCS use was 22.8% of weeks, and 18.1% of weeks were with no TCS use. TCS use was significantly lower in the tralokinumab q2w group compared to the placebo group (p < 0.05).

**TCS use during the continuation treatment period**

At week 16, 46.8% and 46.4% of patients treated with tralokinumab plus TCS and TCS only were using TCS. However, the proportion of patients using TCS increased to 55.3% and 57.3% at week 32 in the tralokinumab plus TCS and TCS only groups, respectively.

### Conclusions

- **Safety**
  - The safety profile at week 32 was comparable with the initial 16-week treatment period.
  - Adverse events were consistent with those observed in previous trials.

- **Statistical analyses**
  - Endpoint assessments were performed at baseline and at each visit.

- **Safety**
  - Adverse events were assessed using a safety monitoring board and were monitored by a steering committee.

- **Statistical analyses**
  - Endpoint assessments were performed using a hierarchical testing procedure and were monitored by a steering committee.

- **TCS use**
  - Mean compliance with returning of TCS tubes was similar in the placebo q2w plus TCS group and the placebo plus placebo group (86% vs. 89%, respectively).

- **Table 1**
  - Patient demographics and disease characteristics at baseline.

---

### Methods

**Methods**

The trial was designed by Abbott, AnaptysBio, Asana Biosciences, Lilly, Galderma Research and Development, GlaxoSmithKline, Glenmark Generics, Kiniksa, LEO Pharma, MedImmune, Menlo Therapeutics, Pfizer, PuriCore, Regeneron, and Sanofi. Andrew E. Pink has acted as a consultant to AbbVie, AnaptysBio, Asana Biosciences, Lilly, Galderma Research and Development, GlaxoSmithKline, Glenmark Generics, Kiniksa, LEO Pharma, MedImmune, Menlo Therapeutics, Pfizer, PuriCore, Regeneron, and Sanofi.

---

### References